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Background: Medical management of heart failure with preserved ejection fraction (HFPEF) remains unclear. This analysis was to assess the 
benefit of ACE-inhibitors (ACEi) and beta blockers (BB) in patients with HFPEF and in heart failure with reduced ejection fraction (HFREF).
methods:  The BACH (Biomarkers in Acute Heart Failure) trial was a prospective, 15-center, international study of 1,641 patients presenting with 
dyspnea. This is a secondary analysis of the BACH trial.
results: Patients with a diagnosis of congestive heart failure (CHF) whom were discharged on a BB or an ACEI had improved survival in both HFPEF 
and HFREF. The propensity score score for being prescribed an ACEi was 0.710 and for a BB was 0.614. A model including all CHF patients and both 
beta blocker and ACEi, ACEi alone, and BB alone demonstrated the most protective effect with ACEi.
conclusions:  Patients with HFPEF and HFREF both demonstrate improved survival when being discharged on ACEi and BB, with ACEi possibly 
having more survival benefit.
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